REFERENCES
1. Huang DQ, Wong VWS, Rinella ME, et al. Metabolic dysfunction-associated steatotic liver disease in adults. Nat Rev Dis Primers. 2025;11:14.
2. Israelsen M, Francque S, Tsochatzis EA, Krag A. Steatotic liver disease. Lancet. 2024;404:1761-78.
3. Byrne CD, Armandi A, Pellegrinelli V, Vidal-Puig A, Bugianesi E. Μetabolic dysfunction-associated steatotic liver disease: a condition of heterogeneous metabolic risk factors, mechanisms and comorbidities requiring holistic treatment. Nat Rev Gastroenterol Hepatol. 2025;22:314-28.
4. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). Obes Facts. 2024;17:374-444.
5. Rivera-Esteban J, Muñoz-Martínez S, Higuera M, et al. Phenotypes of metabolic dysfunction-associated steatotic liver disease-associated hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2024;22:1774-89.e8.
6. Cho SH, Kim G, Lee KN, et al. Metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma in type 2 diabetes mellitus. Diabetes Metab J. 2025;49:1298-307.
7. Jeong S, Oh YH, Ahn JC, et al. Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: a nationwide cohort study. Clin Mol Hepatol. 2024;30:487-99.
8. Njei B, Al-Ajlouni YA. Epigenetic reprogramming in metabolic dysfunction-associated steatotic liver disease: from metabolic memory to precision medicine. Front Physiol. 2026;17:1791638.
9. Hlady RA, Robertson KD. Epigenetic memory of environmental exposures as a mediator of liver disease. Hepatology. 2024;80:451-64.
10. Chen Z, Malek V, Natarajan R. Update: the role of epigenetics in the metabolic memory of diabetic complications. Am J Physiol Renal Physiol. 2024;327:F327-39.
11. Chen Z, Natarajan R. Epigenetic modifications in metabolic memory: what are the memories, and can we erase them? Am J Physiol Cell Physiol 2022;323:C570-82.
12. Puleo J, Polyak K. A Darwinian perspective on tumor immune evasion. Biochim Biophys Acta Rev Cancer. 2022;1877:188671.
13. Volponi C, Gazzillo A, Bonavita E. The tumor microenvironment of hepatocellular carcinoma: untying an intricate immunological network. Cancers. 2022;14:6151.
14. Seyhan D, Allaire M, Fu Y, et al. Immune microenvironment in hepatocellular carcinoma: from pathogenesis to immunotherapy. Cell Mol Immunol. 2025;22:1132-58.
15. Ju Y, Xu K, Chen X, Wu T, Yuan Y. Metabolic-immune microenvironment crosstalk mediating ICI resistance in MASH-HCC. Trends Endocrinol Metab. 2026;37:262-76.
16. Iturbe-Rey S, Maccali C, Arrese M, et al. Lipotoxicity-driven metabolic dysfunction-associated steatotic liver disease (MASLD). Atherosclerosis. 2025;400:119053.
17. Leng Y, Zhang Y, Cheng Y, et al. LIX1L aggravates MASH-HCC progression by reprogramming of hepatic metabolism and microenvironment via CD36. Pharmacol Res. 2025;211:107567.
18. Li J, Li P, Wu X, et al. Protocatechuic acid reduces liver fatty acid uptake in HFD-fed mice associated with the inhibition of DHHC5-mediated CD36 palmitoylation. Mol Nutr Food Res. 2025;69:e70012.
19. Fonseka O, Raja R, Ross C, et al. XBP1s-EDEM2 prevents the onset and development of HFpEF by ameliorating cardiac lipotoxicity. Circulation. 2025;151:1583-605.
20. Robles-Martinez L, Morin KH, Nikolova-Karakashian M. Ceramide homeostasis in hepatic lipid droplets. Biochem Soc Trans. 2025;53:509-18.
21. Van Dijck E, Van Laere S, Logie E, et al. Gradual DNA methylation changes reveal transcription factors implicated in metabolic dysfunction-associated steatotic liver disease progression and epigenetic age acceleration. Clin Epigenetics. 2025;17:138.
22. Zhelezniakova N, Aleksandrova T. The influence of epigenetic mechanisms on the development of metabolic dysfunction associated steatotic liver disease: a review. J Gastrointestin Liver Dis. 2026;35:109-18.
23. Asero C, Franzè MS, Cacciola I, Gangemi S. MASLD under the microscope: how microRNAs and microbiota shape hepatic metabolic disease progression. Int J Mol Sci. 2025;26:8633.
24. Wade H, Pan K, Zhang B, Zheng W, Su Q. Mechanistic role of long non-coding RNAs in the pathogenesis of metabolic dysfunction-associated steatotic liver disease and fibrosis. eGastroenterology. 2024;2:e100115.
25. Belloc E, Calderone V, Naranjo-Suarez S, et al. Posttranscriptional reprogramming controls MASLD progression through chronic ER stress adaptation. Sci Adv. 2026;12:eaea4125.
26. Lui KH, Geisberg JV, Moqtaderi Z, Struhl K. 3’ untranslated regions are modular entities that determine polyadenylation profiles. Mol Cell Biol. 2022;42:e0024422.
27. Mu C, Wang S, Wang Z, et al. Mechanisms and therapeutic targets of mitochondria in the progression of metabolic dysfunction-associated steatotic liver disease. Ann Hepatol. 2025;30:101774.
28. Sharafi F, Rismani E, Rhmanian M, Khosravi A, Zarrabi A, Vosough M. Mitochondrial dysfunction in hepatocellular carcinoma: from metabolism to targeted therapies. Mol Cell Biochem. 2025;480:6015-38.
29. Xu M, Ruan TT, Tang H, et al. Up-regulated programmed cell death protein-1/its ligand 1 expression promotes metabolic dysfunction-associated steatotic liver disease malignant progression. World J Gastrointest Oncol. 2025;17:104842.
30. Nakao K, Maeda S, Iemitsu M. Exercise training improves mitochondrial oxidative energy metabolism through PGC-1α-dependent transcriptional pathway in the aged rat heart. Exp Gerontol. 2026;217:113100.
31. Szekeres R, Priksz D, Bombicz M, et al. Exercise types: physical activity mitigates cardiac aging and enhances mitochondrial function via PKG-STAT3-opa1 axis. Aging Dis. 2024;16:3040-54.
32. Wang Q, Yu P, Liu C, He X, Wang G. Mitochondrial fragmentation in liver cancer: emerging player and promising therapeutic opportunities. Cancer Lett. 2022;549:215912.
33. Wang D, Tian J, Yan Z, et al. Mitochondrial fragmentation is crucial for c-Myc-driven hepatoblastoma-like liver tumors. Mol Ther. 2022;30:1645-60.
34. Jin J, Cheng K, Chen M, Liang H, Zhang W. Immunotherapy resistance in MASLD-related hepatocellular carcinoma: special immune microenvironment and gut microbiota. Int J Biol Sci. 2025;21:5666-90.
35. Kim SJ, Hyun J. Altered lipid metabolism as a predisposing factor for liver metastasis in MASLD. Mol Cells. 2024;47:100010.
36. Yang J, He J, Feng Y, Xiang M. Obesity contributes to hepatocellular carcinoma development via immunosuppressive microenvironment remodeling. Front Immunol. 2023;14:1166440.
37. Xu Y, Li Q, Jiao X. Immunosenescence and metabolic reprogramming in MASLD: an age-dependent immunometabolic vicious cycle and therapeutic opportunities. Front Cell Dev Biol. 2025;13:1650677.
38. Zhao Y, Wang Y, Li F, Yu G. Hypoxia-inducible factors in the immunometabolism of metabolic dysfunction-associated steatotic liver disease (MASLD): molecular mechanisms and therapeutic implications. Front Physiol. 2026;17:1779019.
39. Liu Y. The emerging challenge of non-cirrhotic MASLD-related hepatocellular carcinoma: etiology, immunopathology, and precision oncology. Liver Cancer. 2025;Epub ahead of print.
40. Chaudhary S, Rai R, Pal PB, et al. Western diet dampens t regulatory cell function to fuel hepatic inflammation in metabolic dysfunction-associated steatotic liver disease. Cells. 2026;15:165.
41. Wang H, Tsung A, Mishra L, Huang H. Regulatory T cell: a double-edged sword from metabolic-dysfunction-associated steatohepatitis to hepatocellular carcinoma. EBioMedicine. 2024;101:105031.
42. Papanastasatou M, Verykokakis M. Innate-like T lymphocytes in chronic liver disease. Front Immunol. 2023;14:1114605.
43. Qiu JG, Sang P, Zhou FM, et al. Novel role of MKRN2 in regulating tumor growth through host microenvironment and macrophage M1 to M2 switch. Cancer Lett. 2025;633:218035.
44. Chan MM, Daemen S, Beals JW, et al. Steatosis drives monocyte-derived macrophage accumulation in human metabolic dysfunction-associated fatty liver disease. JHEP Rep. 2023;5:100877.
45. Yang H, Jung S, Choi EY. E3 ubiquitin ligase TRIM38 regulates macrophage polarization to reduce hepatic inflammation by interacting with HSPA5. Int Immunopharmacol. 2025;157:114662.
46. Subramanian P, Hampe J, Tacke F, Chavakis T. Fibrogenic pathways in metabolic dysfunction associated fatty liver disease (MAFLD). Int J Mol Sci. 2022;23:6996.
47. Akkız H, Gieseler RK, Canbay A. Liver fibrosis: from basic science towards clinical progress, focusing on the central role of hepatic stellate cells. Int J Mol Sci. 2024;25:7873.
48. Anton A, Friedman SL, Cogliati B. Hepatic fibrosis and liver cancer. Semin Liver Dis. 2026;46:31-50.
49. Ezhilarasan D, Najimi M. Deciphering the possible reciprocal loop between hepatic stellate cells and cancer cells in the tumor microenvironment of the liver. Crit Rev Oncol Hematol. 2023;182:103902.
50. Zhao H, Wang W, Zhu P, Shi Z. Macrophage-tregs crosstalk: the “hub” of the immune network in MASLD. Front Immunol. 2025;16:1680878.
51. Cho GJ, Kim SM, Yang YM, Seki E. From steatosis to metastasis: microenvironmental reprogramming of the liver in metabolic dysfunction-associated steatotic liver disease. Clin Mol Hepatol. 2026;32:1135-57.
52. Fernandez-Barrena MG, Uriarte I, Sarobe P, Avila MA. Epigenetic mechanisms in HCC immune landscape: therapeutic implications. Semin Immunol. 2025;79:101980.
53. Yi M, Niu M, Xu L, Luo S, Wu K. Regulation of PD-L1 expression in the tumor microenvironment. J Hematol Oncol. 2021;14:10.
54. Li C, Li J, Hu L, Zeng D. Fusobacterium nucleatum enhances immune escape in colorectal cancer by inducing H3K18 lactylation of CD274 (PD-L1) protein through lactate accumulation. APMIS. 2026;134:e70134.
55. Han H, Gong C, Zhang Y, et al. RBM30 recruits DOT1L to activate STAT1 transcription and drive immune evasion in hepatocellular carcinoma. Oncogene. 2025;44:3955-73.
56. Yang S, Xie S, Shi X, et al. Characterizing HDAC pathway copy number variation in pan-cancer. Pathol Oncol Res. 2022;28:1610288.
57. Zhou Y, Bastian IN, Long MD, et al. Activation of NF-κB and p300/CBP potentiates cancer chemoimmunotherapy through induction of MHC-I antigen presentation. Proc Natl Acad Sci U S A. 2021;118:e2025840118.
58. Huang Y, Yang X, Meng Y, et al. The hepatic senescence-associated secretory phenotype promotes hepatocarcinogenesis through Bcl3-dependent activation of macrophages. Cell Biosci. 2021;11:173.
59. Herbstein F, Sapochnik M, Attorresi A, et al. The SASP factor IL-6 sustains cell-autonomous senescent cells via a cGAS-STING-NFκB intracrine senescent noncanonical pathway. Aging Cell. 2024;23:e14258.
60. Jian X, Cheng C, Lu W, Peng H, Yang D. Histone lactylation: unveiling a novel pathway for the impact of lactate on physiological and pathological processes (Review). Int J Mol Med. 2026;57:1-12.
61. Huang M. Histone lactylation in gastrointestinal cancers: developing immunotherapeutic drugs targeting epigenetics. Arch Pharm Res. 2025;48:831-42.
62. Liu S, Pan Y, Liu W, et al. Lactylation-driven MVP upregulation boosts immunotherapy resistance by inhibiting PD-L1 degradation in hepatocellular carcinoma. J Immunother Cancer. 2025;13:e012230.
63. Zhang H, Zhu X, Friesen TJ, et al. Annexin A2/TLR2/MYD88 pathway induces arginase 1 expression in tumor-associated neutrophils. J Clin Invest. 2022;132:e153643.
64. Herbrich S, Baran N, Cai T, et al. Overexpression of CD200 is a stem cell-specific mechanism of immune evasion in AML. J Immunother Cancer. 2021;9:e002968.
65. Pandit M, Kil YS, Ahn JH, et al. Methionine consumption by cancer cells drives a progressive upregulation of PD-1 expression in CD4 T cells. Nat Commun. 2023;14:2593.
66. Yalley NN, Armasu SM, Fan WZ, et al. Associations of S-adenosylmethionine and S-adenosylhomocysteine with hepatocellular carcinoma. Metabolites. 2025;15:740.
67. Huang Y, Chen Z, Wu H. Advances in methionine metabolism for the remodeling of the tumor metabolic-immune microenvironment. J China Pharm Univ. 2025;56:280-6.
68. Guan Y, Kim Y, Wang Y, et al. Adipocyte death promotes hepatic infiltration of S100A8+ macrophages and steatotic liver disease progression in mice. J Clin Invest. 2025;135:e190635.
69. Guo WW, Dongzhi C, Ma T, et al. CCT2 orchestrates glycolysis and exosome-mediated M2 macrophage polarization in HCC tumorigenesis. Int J Biol Sci. 2026;22:3389-410.
70. Wang B, Pi Q, Mohsin A, Gao WQ, Guo M, Xu H. Exosomal miR-1246 of adipose stem cells attenuates obesity by polarizing M2 macrophages, reducing fat mass, and beiging of white adipose tissue. J Adv Res. 2026;81:195-209.
71. Zhao H, Shang Q, Pan Z, et al. Exosomes from adipose-derived stem cells attenuate adipose inflammation and obesity through polarizing M2 macrophages and beiging in white adipose tissue. Diabetes. 2018;67:235-47.
72. Jennings H, McMorrow S, Chlebeck P, et al. Normothermic liver perfusion derived extracellular vesicles have concentration-dependent immunoregulatory properties. J Extracell Vesicles. 2024;13:e12485.
73. Boonkaew B, Charoenthanakitkul D, Suntornnont N, Ariyachet C, Tangkijvanich P. Extracellular vesicles in metabolic dysfunction-associated steatotic liver disease: From intercellular signaling to clinical translation. World J Hepatol. 2025;17:108259.
74. Xu K, Wu Q, Lingyun Z, et al. Extracellular vesicles as a promising platform of precision medicine in liver cancer. Pharmacol Res. 2025;217:107800.
75. Song MJ, Malhi H. The unfolded protein response and hepatic lipid metabolism in non alcoholic fatty liver disease. Pharmacol Ther. 2019;203:107401.
76. Karin M, Kim JY. Endoplasmic reticulum stress at the forefront of fatty liver diseases and cancer. Pharmacol Rev. 2025;77:100096.
77. Du H, Li J, Wei X, et al. Methylparaben induces hepatic glycolipid metabolism disorder by activating the IRE1α-XBP1 signaling pathway in male mice. Environ Int. 2024;184:108445.
78. Batista A, Rodvold JJ, Xian S, et al. IRE1α regulates macrophage polarization, PD-L1 expression, and tumor survival. PLoS Biol. 2020;18:e3000687.
79. Yi X, Wang H, Yang Y, et al. SIRT7 orchestrates melanoma progression by simultaneously promoting cell survival and immune evasion via UPR activation. Signal Transduct Target Ther. 2023;8:107.
80. Wu Y, Luo H, Pan Z, Chen W, Bi L. Bidirectional crosstalk between ER stress and lipid metabolism: from proteostasis to tumor adaptation. Cell Death Discov. 2025;12:37.
81. Myint M, Oppedisano F, De Giorgi V, et al. Inflammatory signaling in NASH driven by hepatocyte mitochondrial dysfunctions. J Transl Med. 2023;21:757.
82. Hsieh CH. Selective autophagy in hepatocellular carcinoma: mechanisms, roles and therapeutic implications (Review). Exp Ther Med. 2025;30:245.
83. Zapatería B, Arias E. Aging, cancer, and autophagy: connections and therapeutic perspectives. Front Mol Biosci. 2024;11:1516789.
84. Niture S, Lin M, Rios-Colon L, Qi Q, Moore JT, Kumar D. Emerging roles of impaired autophagy in fatty liver disease and hepatocellular carcinoma. Int J Hepatol. 2021;2021:6675762.
85. Zhou Q, Shi Y, Chen C, Wu F, Chen Z. A narrative review of the roles of indoleamine 2,3-dioxygenase and tryptophan-2,3-dioxygenase in liver diseases. Ann Transl Med. 2021;9:174.
86. Dong F, Annalora AJ, Murray IA, et al. Endogenous tryptophan-derived ah receptor ligands are dissociated from CYP1A1/1B1-dependent negative-feedback. Int J Tryptophan Res. 2023;16:11786469231182508.
87. Diao X, Shang Q, Guo M, et al. Structural basis for the ligand-dependent activation of heterodimeric AHR-ARNT complex. Nat Commun. 2025;16:1282.
88. Dong Z, Dai H, Zhang X, et al. The IDO1/AhR-HIF-1α metabolic axis: ARNT competition as a central antagonistic switch in autoimmune pathogenesis. Front Immunol. 2026;17:1772536.
89. Cha D, Choi SJ, Park H, et al. Preclinical pharmacological and toxicological evaluation of SB5794, a novel aryl hydrocarbon receptor modulator on the kynurenine-AhR axis. Biomol Ther. 2026;34:146-53.
90. Venkateswaran N, Lafita-Navarro MC, Hao YH, et al. MYC promotes tryptophan uptake and metabolism by the kynurenine pathway in colon cancer. Genes Dev. 2019;33:1236-51.
91. Lachin JM, Nathan DM; DCCT/EDIC Research Group. Understanding metabolic memory: the prolonged influence of glycemia during the diabetes control and complications trial (DCCT) on future risks of complications during the study of the epidemiology of diabetes interventions and complications (EDIC). Diabetes Care. 2021;44:2216-24.
92. Zhang Y, Wang Y, Qiao Y, et al. Targeting the NAD+-SIRT3 axis to mitigate metabolic memory in diabetic kidney disease. Ren Fail. 2026;48:2648912.
93. Wang Q, Guo Y, Chen S, et al. Histidine triad nucleotide-binding protein 2 attenuates metabolic dysfunction-associated steatotic liver disease through NAD+-dependent sirtuin-3 activation. Exp Mol Med. 2025;57:990-1004.
94. Wang H, Sun Y, Pi C, et al. Nicotinamide mononucleotide supplementation improves mitochondrial dysfunction and rescues cellular senescence by NAD+/Sirt3 pathway in mesenchymal stem cells. Int J Mol Sci. 2022;23:14739.
95. Kuo CC, Chuang MH, Li CH, et al. Glucagon-like peptide-1 receptor agonists and liver outcomes in patients with MASLD and type 2 diabetes. Aliment Pharmacol Ther. 2025;61:1163-74.
96. Cheraghpour M, Hatami B, Singal AG. Lifestyle and pharmacologic approaches to prevention of metabolic dysfunction-associated steatotic liver disease-related hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2025;23:685-94.e6.
97. Fazeli SA, Soleimani Samarkhazan H. Metabolic memory following metabolic bariatric surgery: mechanisms, clinical implications, and strategies for long-term success. Obes Surg. 2025;35:5606-24.
98. Zhang Y, Xiong S, Zheng W, et al. Reshaping the immunosuppressive niche in hepatocellular carcinoma: crosstalk networks, metabolic reprogramming, and therapeutic strategies. Biochem Pharmacol. 2026;248:117858.
99. Sun J, Yang F, Li Y, Li S, Song J. Neutrophil polarization landscapes in HCC: from immunosuppressive niches to antitumor immunity resuscitation. Cancer Lett. 2026;651:218527.
100. Nouri K, Asadollahei N, Haghir-Sharif-Zamini Y, et al. T cell exhaustion in hepatocellular carcinoma: a substantial barrier in immunotherapy. J Cell Mol Med. 2026;30:e71044.
101. Duan Q, Liu P, Chen H, Ding Y, Xu X. Identification of metabolism regulators as diagnostic markers for ulcerative colitis and their correlation with immune infiltration. Pol J Pathol. 2025;76:110-9.
102. Tu Y, Wu H, Zhong C, et al. Pharmacological activation of STAT1-GSDME pyroptotic circuitry reinforces epigenetic immunotherapy for hepatocellular carcinoma. Gut. 2025;74:613-27.
103. Hong YK, Li Y, Pandit H, et al. Epigenetic modulation enhances immunotherapy for hepatocellular carcinoma. Cell Immunol. 2019;336:66-74.
104. Kang I, Theodoropoulos G, Wangpaichitr M. Targeting the kynurenine pathway: another therapeutic opportunity in the metabolic crosstalk between cancer and immune cells. Front Oncol. 2024;14:1524651.
105. Yoo KH, Szymura S, Dong Z, Kandel A, Cha SC, Kwak LW. Predictive markers for the efficacy of CAR T-cell therapy: the interplay between CAR T-cell fitness and systemic immunity. Blood Adv. 2025;9:6432-42.
106. Yin X, Zhao X, Shen Y, et al. Nanoparticle-mediated dual targeting of stromal and immune components to overcome fibrotic and immunosuppressive barriers in hepatocellular carcinoma. J Control Release. 2025;383:113783.
107. Zhang Y, Rui W, Liu X, et al. Lipid metabolism in liver transplantation: from challenge to chance. Metab Target Organ Damage 2025;510.20517/mtod.2025.03.
108. Liu Q, Fan C, Xu B, et al. Thrombospondin 1 is associated with MASH and hepatic macrophage inflammatory responses via CD47. Metab Target Organ Damage 2026;6:25.
